Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma

Journal of Dermatology

Volumn 38, Issue 4, 2011, Pages 321-334

  Torii, Hideshi ^a   Nakagawa, Hidemi ^b  

^a Social Insurance Central General Hospital   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

infliximab; psoriatic arthritis; psoriatic erythroderma; pustular psoriasis; tumor necrosis factor

Indexed keywords

INFLIXIMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL EXAMINATION; CLINICAL PRACTICE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHRODERMA; FEVER; HERPES SIMPLEX; HUMAN; HYPERTENSION; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALAISE; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PSORIATIC ERYTHRODERMA; PUSTULAR PSORIASIS; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; FEMALE; JAPAN; MALE; MIDDLE AGED; MULTICENTER STUDY; NEWBORN EXFOLIATIVE DERMATITIS; PARAPSORIASIS;

ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; DERMATITIS, EXFOLIATIVE; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PARAPSORIASIS; PSORIASIS; TREATMENT OUTCOME;

EID: 79961179812     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2011.01209.x     Document Type: Article

References (21)

1. Antoni C, Dechant C, Hanns-Martin Lorenz PD, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002; 47: 506-512. (Pubitemid 35291372)
2. Oh CJ, Das KM, Gottlieb AB,. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol 2000; 42: 829-830. (Pubitemid 30252891)
3. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374. (Pubitemid 41443403)
4. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31.
5. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves sighs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 1150-1157. (Pubitemid 41113349)
6. Torii H, Nakagawa H, the Japanese Infliximab Study investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled, multicenter trial. J Dermatol Sci 2010; 59: 40-49.
7. Elewski BE,. Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol 2002; 47: 796-797. (Pubitemid 35239351)
8. Rongioletti F, Borenstein M, Kirsner R, Kerdel F,. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. J Dermatolog Treat 2003; 14: 222-225. (Pubitemid 37474533)
9. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244. (Pubitemid 8387357)
10. Rich P, Scher RK,. Nail Psoriasis Severity Index: a useful tool for evalution of nail psoriasis. J Am Acad Dermatol 2003; 49: 206-212. (Pubitemid 36951265)
11. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-735.
12. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP,. Assessment of patient satisfaction in activities of daily living using a modified Standford Health Assessment Questionnaire. Arthritis Rheum 1983; 26: 1346-1353. (Pubitemid 14231480)
13. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216. (Pubitemid 24194579)
14. Khilji FA, Gonzalez M, Finlay AY,. Clinical meaning of change in dermatology life quality index scores. Br J Dermatol 2002; 147 (Suppl. 62): 50 (Abstract).
15. Bonifati C, Carducci M, Cordiali Fei P, et al. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients-relationships with disease severity. Clin Exp Dermatol 1994; 19: 383-387. (Pubitemid 24308596)
16. Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS,. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24: 518-523. (Pubitemid 27153418)
17. Bedini C, Nasorri F, Girolomoni G, Pità O, Cavani A,. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function. Br J Dermatol 2007; 157: 249-258. (Pubitemid 47083831)
18. Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005; 175: 2721-2729. (Pubitemid 41113889)
19. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007; 204: 3183-3194.
20. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the infliximab multinational psoriatic arthritis controlled trial (IMPACT). J Rheumatol 2008; 35: 869-876. (Pubitemid 351747130)
21. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 189-194. (Pubitemid 351183307)